Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zenapax in Adult T-Cell Leukemia
NCT00001941Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Dec 1999
- Primary completion
- Feb 2011
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of daclizumab in adult T-cell leukemia-lymphoma (ATLL), sponsored by National Cancer Institute. Started Dec 1999; status: completed.
02
Drugs
daclizumab
03
Conditions
adult T-cell leukemia-lymphoma (ATLL)
Beyond the preview
Go deeper on NCT00001941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00001941.